X Anton Alvarez

Summary

Affiliation: Hospital Universitario
Country: Spain

Publications

  1. ncbi Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
    X A Alvarez
    Euroespes Biomedical Research Centre, Santa Maria de Babio, 15166 Bergondo, La Coruna, Spain
    Eur J Neurol 18:59-68. 2011
  2. ncbi A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
    X A Alvarez
    Euroespes Biomedical Research Centre, Santa Maria de Babio, Bergondo, La Coruna, Spain
    Eur J Neurol 13:43-54. 2006
  3. ncbi Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
    Antón Alvarez
    EuroEspes Biomedical Research Center, 15166 A Coruña, Spain
    Neurobiol Aging 28:533-6. 2007
  4. ncbi Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury
    X Anton Alvarez
    Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergondo, A Coruna, Spain
    J Neural Transm 115:683-92. 2008
  5. ncbi Reduced TNF-? and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin
    X Anton Alvarez
    Department of Neuropharmacology, Euroespes Biomedical Research Centre, A Coruna, Spain
    Int J Neuropsychopharmacol 12:867-72. 2009
  6. ncbi Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil
    X Anton Alvarez
    Euroespes Biomedical Research Centre, A Coruna, Spain
    Curr Alzheimer Res 8:583-91. 2011
  7. ncbi Cerebrolysin in Alzheimer's disease
    X Anton Alvarez
    Euroespes Biomedical Research Centre, A Coruna, Spain
    Drugs Today (Barc) 47:487-513. 2011

Collaborators

  • Ramon Cacabelos
  • L Corzo
  • Patricio Fuentes
  • X Anton Alvarez
  • X A Alvarez
  • H Moessler
  • C Linares
  • E Granizo
  • M Aleixandre
  • C Sampedro
  • Manuel García-Fantini
  • E Doppler
  • Carolina Sampedro
  • V Couceiro
  • Herbert Moessler
  • M Vargas
  • Manuel Aleixandre
  • Antón Alvarez
  • W Baurecht
  • M García-Fantini
  • Carlos Linares
  • Iván Tellado
  • Dafin Muresanu
  • Jesus Figueroa
  • Andres Gonzalez
  • Carolina Sanpedro
  • L Fernandez-Novoa
  • M Laredo
  • M Varela
  • D Muresanu

Detail Information

Publications7

  1. ncbi Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
    X A Alvarez
    Euroespes Biomedical Research Centre, Santa Maria de Babio, 15166 Bergondo, La Coruna, Spain
    Eur J Neurol 18:59-68. 2011
    ..Results of the mild AD subgroup (ITT data set: N = 118; MMSE: 21-25) are also presented...
  2. ncbi A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
    X A Alvarez
    Euroespes Biomedical Research Centre, Santa Maria de Babio, Bergondo, La Coruna, Spain
    Eur J Neurol 13:43-54. 2006
    ..The percentage of patients reporting adverse events was similar across all study groups. Cere treatment was well tolerated and led to significant, dose-dependent improvement of cognition and global clinical impression...
  3. ncbi Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
    Antón Alvarez
    EuroEspes Biomedical Research Center, 15166 A Coruña, Spain
    Neurobiol Aging 28:533-6. 2007
    ..In addition, the combined determination of TNF-alpha and IGF-I might be useful to monitor anti-inflammatory and/or neurotrophic drug effects in AD...
  4. ncbi Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury
    X Anton Alvarez
    Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergondo, A Coruna, Spain
    J Neural Transm 115:683-92. 2008
    ..Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials...
  5. ncbi Reduced TNF-? and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin
    X Anton Alvarez
    Department of Neuropharmacology, Euroespes Biomedical Research Centre, A Coruna, Spain
    Int J Neuropsychopharmacol 12:867-72. 2009
    ..These results showing for the first time the opposite influence of one anti-dementia treatment on serum TNF-? and IGF-I suggest the contribution of both factors to the clinical effects of Cere, and probably other drugs...
  6. ncbi Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil
    X Anton Alvarez
    Euroespes Biomedical Research Centre, A Coruna, Spain
    Curr Alzheimer Res 8:583-91. 2011
    ..The convenience of exploring long-term synergistic effects of this combined therapy is suggested...
  7. ncbi Cerebrolysin in Alzheimer's disease
    X Anton Alvarez
    Euroespes Biomedical Research Centre, A Coruna, Spain
    Drugs Today (Barc) 47:487-513. 2011
    ..Although long-term studies are needed, the data available suggest that Cerebrolysin is effective as monotherapy and constitutes a promising option for combined therapy in Alzheimer's disease...